Infosys teams up with Univ. of Illinois in precision medicine play

Digital services and consulting company Infosys has teamed up with the University of Illinois Urbana-Champaign (UIUC) have formed a partnership to develop new technologies and systems in precision medicine. The partnership is the latest example of organizational collaboration aimed at precision medicine solutions.

Infosys’ Nia platform, which has advance machine learning and AI capabilities, will combine with UIUC’s expertise in computing systems, bioinformatics and genomic applications to improve preventive care and the predictability of treatment outcomes from disease.

As part of the partnership, Infosys will also become a member of the Center for Computational Biotechnology and Genomic Medicine (CCBGM), which is a collaboration between UIUC and Mayo Clinic Center for Individualized Medicine.

“The partnership between Infosys and UIUC along with our membership in CCBGM opens up a lot of potential for Infosys’ work in the healthcare industry,” Venky Ananth, senior vice president, head of healthcare at Infosys, said in a statement. “Not only do we have an opportunity to develop technologies and solutions that can improve and enhance patient care and management, but we also get a chance to collaborate with some of the finest minds on the new frontiers of healthcare innovation.”

The CCBGM also relies heavily on industry partners and aims to create breakthroughs in precision medicine.

“The future of precision medicine, which allows tailoring diagnosis and treatment to each patient in order to optimize outcome, is dependent on the ability to jointly analyze large datasets of heterogeneous biological (genomic, metabolic, neuroimaging, etc.) and clinical measures while incorporating key clinical domain knowledge,” Professor Ravishankar K Iyer, Electrical and Computer Engineering, University of Illinois and CoPI of the CCBGM. Said in a statement. “This is a complex challenge and will require innovations in both data-driven analytics and system design to succeed.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.